IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.088
EU - Europa 8.823
AS - Asia 6.769
SA - Sud America 837
AF - Africa 98
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 7
AN - Antartide 1
Totale 27.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.912
SG - Singapore 2.861
RU - Federazione Russa 2.706
CN - Cina 1.824
IE - Irlanda 1.026
IT - Italia 1.014
UA - Ucraina 914
SE - Svezia 792
FR - Francia 714
BR - Brasile 674
GB - Regno Unito 666
TR - Turchia 643
VN - Vietnam 616
DE - Germania 483
IN - India 278
FI - Finlandia 168
BD - Bangladesh 117
HK - Hong Kong 113
CA - Canada 86
AT - Austria 62
PL - Polonia 60
AR - Argentina 58
MX - Messico 57
JP - Giappone 52
BE - Belgio 50
IQ - Iraq 48
NL - Olanda 34
ES - Italia 31
ZA - Sudafrica 31
CZ - Repubblica Ceca 30
PK - Pakistan 27
SA - Arabia Saudita 21
CO - Colombia 20
KR - Corea 20
EG - Egitto 19
EC - Ecuador 18
UZ - Uzbekistan 18
EU - Europa 17
CL - Cile 16
ID - Indonesia 15
PH - Filippine 15
VE - Venezuela 14
AE - Emirati Arabi Uniti 13
AL - Albania 12
LT - Lituania 12
PY - Paraguay 12
RO - Romania 12
JO - Giordania 11
MA - Marocco 10
BO - Bolivia 9
IL - Israele 9
KE - Kenya 9
LB - Libano 9
PE - Perù 9
TN - Tunisia 8
AU - Australia 7
DZ - Algeria 7
IR - Iran 7
JM - Giamaica 7
UY - Uruguay 7
AZ - Azerbaigian 6
CH - Svizzera 6
DO - Repubblica Dominicana 6
NP - Nepal 6
GR - Grecia 5
GT - Guatemala 5
OM - Oman 5
SN - Senegal 5
TH - Thailandia 5
DK - Danimarca 4
ET - Etiopia 4
PT - Portogallo 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
GE - Georgia 3
HR - Croazia 3
KG - Kirghizistan 3
MT - Malta 3
MY - Malesia 3
NI - Nicaragua 3
TW - Taiwan 3
AM - Armenia 2
BH - Bahrain 2
CI - Costa d'Avorio 2
DM - Dominica 2
HN - Honduras 2
HU - Ungheria 2
KW - Kuwait 2
KZ - Kazakistan 2
MM - Myanmar 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
Totale 27.629
Salva come PNG Salva come JPEG
Città #
Singapore 2.171
Chandler 1.479
San Jose 1.257
Jacksonville 1.168
Dublin 1.016
Ashburn 738
Dallas 563
Beijing 476
Princeton 466
Southend 414
Izmir 378
Nanjing 342
Los Angeles 292
Wilmington 225
Santa Clara 202
Ho Chi Minh City 199
The Dalles 196
Dearborn 189
New York 179
Ann Arbor 177
Cambridge 174
Altamura 167
Council Bluffs 166
Boardman 148
Chieti 140
Nanchang 127
Hanoi 122
Buffalo 118
Tongling 111
Munich 103
Hong Kong 100
Houston 97
Woodbridge 93
Moscow 81
São Paulo 71
Redondo Beach 70
Dong Ket 68
Shenyang 63
Hebei 60
Orem 59
Rome 59
Kunming 54
Tianjin 51
Brussels 48
Brooklyn 47
Tokyo 46
Vienna 45
Washington 45
Warsaw 44
Chicago 43
Jiaxing 40
London 39
Denver 38
Norwalk 38
Milan 37
Nuremberg 37
Atlanta 35
Montreal 35
Frankfurt am Main 33
Pescara 32
Stockholm 32
Boston 30
Da Nang 29
Helsinki 28
Hyderabad 28
Seattle 27
Chennai 26
Johannesburg 25
Changsha 23
Poplar 23
Brno 22
Falls Church 22
Haiphong 22
Hangzhou 22
Mexico City 22
Mumbai 22
San Francisco 22
Manchester 21
Belo Horizonte 20
Hefei 20
Phoenix 20
Rio de Janeiro 20
Kocaeli 19
Seoul 19
Amsterdam 18
Baghdad 18
Toronto 18
San Mateo 17
Lanzhou 16
St Louis 16
Tashkent 16
Turku 16
Düsseldorf 15
Auburn Hills 14
Augusta 14
Shanghai 14
Tappahannock 14
Cairo 13
Changchun 13
Dhaka 13
Totale 15.920
Salva come PNG Salva come JPEG
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 863
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 848
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer 767
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 306
90K (Mac-2 BP) in human milk 236
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 211
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 192
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 188
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 184
A multidisciplinary group for prostate cancer management: A single institution experience 183
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 180
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 178
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 174
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 167
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 167
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 166
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 166
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 166
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 162
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 161
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 161
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 160
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 159
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 158
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 157
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 156
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 156
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 156
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 155
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 154
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 151
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 151
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 150
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 148
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 148
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 148
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 147
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 146
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 145
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 144
New Targets for Therapy in Pancreatic Cancer 144
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 144
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 142
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 142
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 140
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 140
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 138
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 137
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 136
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 136
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 135
Chemotherapy preoperative for the management of breast cancer locally advanced 134
Treatment of metastatic colorectal cancer patients 75 years old in clinical practice: A multicenter analysis 134
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 134
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 133
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 132
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 132
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 131
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 131
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 130
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 130
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 130
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 129
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 128
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 128
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 127
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 127
A Flow cytometric study of early gastric cancer 126
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 126
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 125
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 125
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 125
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 124
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 124
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 123
Interleukin-30 Promotes Breast Cancer Growth and Progression 123
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 123
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 123
Principali effetti collaterali delle terapie mediche 122
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 122
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 122
DNA ploidy and S-phase fraction in pulmonary carcinoids. 121
Tumor-derived microvesicles: The metastasomes. 121
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 121
Prognostic value of 90K protein in HIV infection 120
Surgical treatment of adrenal metastases from non small cell lung cancer 120
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 120
Tyrosine kinase inhibitors 120
Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-centre study 120
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 120
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 120
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 118
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 118
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 117
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 117
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 117
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 117
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 116
Unknown primary tumors 116
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy 116
Totale 16.327
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021130 0 0 0 0 0 0 0 0 0 0 0 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/202610.585 674 378 979 925 838 588 1.529 495 2.812 716 449 202
Totale 28.489